Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Shares Outstanding (Weighted Average) (2016 - 2025)

Ptc Therapeutics has reported Shares Outstanding (Weighted Average) over the past 14 years, most recently at $79.5 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $79.5 million for Q4 2025, up 3.5% from a year ago — trailing twelve months through Dec 2025 was $79.5 million (up 3.5% YoY), and the annual figure for FY2025 was $79.5 million, up 3.5%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $79.5 million at Ptc Therapeutics, up from $78.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for PTCT hit a ceiling of $79.5 million in Q4 2025 and a floor of $70.2 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $74.7 million (2023), compared with a mean of $74.3 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 12.5% in 2021 and later increased 1.25% in 2022.
  • Ptc Therapeutics' Shares Outstanding (Weighted Average) stood at $70.5 million in 2021, then grew by 1.79% to $71.7 million in 2022, then increased by 4.34% to $74.8 million in 2023, then rose by 2.68% to $76.8 million in 2024, then rose by 3.5% to $79.5 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $79.5 million (Q4 2025), $78.5 million (Q3 2025), and $78.4 million (Q2 2025) per Business Quant data.